Edward Van Der Horst

Edward van der Horst is a molecular pharmacologist with a strong focus on antibody drug development across diverse target classes in oncology. He has 20 years of research and development experience from Zenith Epigenetics Ltd, Igenica Biotherapeutics Inc., OncoMed Pharmaceuticals, Tularik, Inc. (now Amgen) and U3 Pharma GmbH (now Daiichi-Sankyo). Edward’s contributions and discoveries have led to the clinical evaluation of several novel drug candidates at Igenica Biotherapeutics and OncoMed Pharmaceuticals, as well as to the first clinical stage anti-HER3 antibody at U3 Pharma GmbH. He received his postdoctoral training at Tularik, Inc. Edward earned his Ph.D. in biochemistry from the Max-Planck Institute of Biochemistry and conducted his master’s thesis at Max-Planck Institute of Neurobiology. He graduated with a master’s degree of chemistry from the Ludwig Maximilian University of Munich.